Article thumbnail

Fetal Tachyarrhythmia - Part II: Treatment

By Martijn A Oudijk, Gerard HA Visser and Erik J Meijboom

Abstract

The decision to initiate pharmacological intervention in case of fetal tachycardia depends on several factors and must be weighed against possible maternal and/or fetal adverse effects inherent to the use of antiarrhythmics. First, the seriousness of the fetal condition must be recognized. Many studies have shown that in case of fetal tachycardia, there is a significant predisposition to congestive heart failure and subsequent development of fetal hydrops and even sudden cardiac death1,2,3 Secondly, predictors of congestive heart failure have been suggested in several studies, such as the percentage of time that the tachycardia is present, the gestational age at which the tachycardia occurs4, the ventricular rate5 and the site of origin of the tachycardia6. However, the sensitivity of these predictors is low and they are therefore clinically not very useful. In addition, hemodynamic compromise may occur in less than 24 - 48 hours as has been shown in the fetal lamb7 and in tachycardic fetuses8,9. On the other hand, spontaneous resolution of the tachycardia has also been described10. Thirdly, transplacental management of fetuses with tricuspid regurgitation11, congestive heart failure or fetal hydrops is difficult12,13, probably as a result of limited transplacental transfer of the antiarrhythmic drug14,15. In case of fetal hydrops, conversion rates are decreased and time to conversion is increased13. Treatment of sustained fetal tachycardia is therefore to be preferred above expectant management, although some centers oppose this regimen and suggest that in cases with (intermittent) fetal SVT not complicated by congestive heart failure or fetal hydrops, conservative management and close surveillance might be a reasonable alternative16,17,18

Topics: Indian Pacing and Electrophysiology Journal
Publisher: Indian Pacing and Electrophysiology Group
Year: 2004
OAI identifier: oai:cogprints.org:4183

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2004). Amiodarone therapy for drug-refractory fetal tachycardia. Circulation.
  2. (1992). Amiodarone therapy of intractable atrial flutter in a premature hydropic neonate. Pediatr Cardiol doi
  3. (1990). Atrial tachycardia causes hydrops in fetal lambs.
  4. Cardiac ultrasound of the fetus.
  5. (1995). Direct fetal administration of adenosine for the termination of incessant supraventricular tachycardia.
  6. (1993). Epidemiology of preterm birth.
  7. Evaluation of fetal arrhythmias by echocardiography.
  8. (2000). Fetal arrhythmias. Prog Pediatr Cardiol
  9. (1998). Fetal cardiac arrhythmias: diagnosis and therapy.
  10. (1991). Fetal supraventricular tachycardia and hydrops fetalis: combined intensive, direct, and transplacental therapy. Obstet Gynecol.
  11. (1996). Fetal supraventricular tachycardia complicated by hydrops fetalis: a role for direct fetal intramuscular therapy.
  12. (1991). Fetal tachyarrhythmias: transplacental and direct treatment of the fetus. A report of 60 cases.
  13. (2003). Fetal tachycardia, diagnosis and treatment and the fetal QT interval in hypoxia. Thesis Utrecht
  14. Flecainide in the intrauterine treatment of fetal supraventricular tachycardia. doi
  15. (1996). Gidding SS. Fetal tachycardia: mechanisms and predictors of hydrops fetalis.
  16. Insufficient transplacental digoxin transfer in severe hydrops fetalis.
  17. (2004). Late second stage rupture of the uterus and bladder with vaginal birth after cesarean section: a case report and review of the literature.
  18. Management strategy for fetal tachycardia.
  19. (2000). Meijboom EJ. Sotalol in the treatment of fetal dysrhythmias. Circulation. doi
  20. (2003). Meijboom EJ. Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. J Am Coll Cardiol. doi
  21. Mortality and morbidity in patients receiving encainide, flecainide, or placebo, the cardiac arrhythmia suppression trial.
  22. Obstetric importance, diagnosis, and management of fetal tachycardias.
  23. outcome and follow-up of fetal tachycardia.
  24. Placenta accreta—summary of 10 years: a survey of 310 cases.
  25. Prenatal ultrasound may predict fetal response to therapy in non-hydropic fetuses with supraventricular tachycardia.
  26. (1996). Rate based management of fetal supraventricular tachycardia.
  27. (1996). Rate-based management of fetal supraventricular tachycardia.
  28. Repeated intravascular treatment with amiodarone in a fetus with refractory supraventricular tachycardia and hydrops fetalis. doi
  29. Risk of uterine rupture during labor among women with a prior cesarean delivery.
  30. Serum digoxin concentrations in the human fetus, neonate and infant.
  31. Successful treatment of refractory supraventricular tachycardia by repeat intravascular injection of amiodarone with long term follow-up. doi
  32. (1997). Supraventricular tachycardia in the fetus: conservative management in the absence of hemodynamic compromise.
  33. The contribution of low birth weight to infant mortality and childhood morbidity.
  34. (1995). The efficacy of flecainide versus digoxin in the management of fetal supraventricular tachycardia.
  35. Transfer of digoxin across the placenta and into breast milk.
  36. (1985). Treatment of fetal cardiac arrhythmias.
  37. Treatment of fetal supraventricular tachyarrhythmias.
  38. Treatment of fetal supraventricular tachycardia with flecainide acetate after digoxin failure.